Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: soubeyran i. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.
Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group. Blons H, et al. PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013. PLoS One. 2013. PMID: 23935912 Free PMC article.
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Callens C, et al. Among authors: soubeyran i. J Natl Cancer Inst. 2021 Jul 1;113(7):917-923. doi: 10.1093/jnci/djaa193. J Natl Cancer Inst. 2021. PMID: 33372675 Free PMC article. Clinical Trial.
Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies.
Koeppel F, Muller E, Harlé A, Guien C, Sujobert P, Trabelsi Grati O, Kosmider O, Miguet L, Mauvieux L, Cayre A, Salgado D, Preudhomme C, Karayan-Tapon L, Tachon G, Coulet F, Lespagnol A, Beroud C, Leroy K, Rouleau E, Soubeyran I. Koeppel F, et al. Among authors: soubeyran i. Eur J Cancer. 2021 Dec;159:1-15. doi: 10.1016/j.ejca.2021.08.047. Epub 2021 Oct 23. Eur J Cancer. 2021. PMID: 34700215
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: soubeyran i. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy F, Souquet PJ, Cloarec N, Giroux-Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B. Barlesi F, et al. Among authors: soubeyran i. Clin Cancer Res. 2022 Sep 15;28(18):4018-4026. doi: 10.1158/1078-0432.CCR-22-0371. Clin Cancer Res. 2022. PMID: 35802649 Clinical Trial.
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Martin Romano P, Ngo Camus M, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: soubeyran i. Ann Oncol. 2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089. Epub 2022 Sep 17. Ann Oncol. 2022. PMID: 36122799 Free article. No abstract available.
119 results